The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once
daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly
diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hvidovre University Hospital
Collaborators:
Aalborg Universitetshospital Aalborg University Hospital Aarhus University Hospital Bispebjerg Hospital Hillerod Hospital, Denmark Hospital of South West Denmark Odense University Hospital Steno Diabetes Center Steno Diabetes Center Copenhagen